<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777162</url>
  </required_header>
  <id_info>
    <org_study_id>Tislelizumab plus Anlotinib</org_study_id>
    <nct_id>NCT04777162</nct_id>
  </id_info>
  <brief_title>Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer</brief_title>
  <official_title>Efficacy and Safety of Tislelizumab Plus Anlotinib in PD-1/PD-L1 Resistant Metastatic Gastric or Colorectal Cancer: a Single Arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunotherapy acquired resistance was observed in clinical practice. The investigators&#xD;
      intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-angiogenesis seems have positive effects on tumor immune microenvironment. the&#xD;
      combination of PD-1/PD-L1 inhibitors and TKIs exhibited favorable efficacy on&#xD;
      gastrointestinal malignancies. Here the investigators want to examine the efficacy and&#xD;
      survival benefit from the combination therapy to PD-1 acquired resistance patients, which&#xD;
      turns out to be critical issues in recent years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>the rate of patients reached PR or CR based on RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>the time from recruiting to death or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>the time from recruiting to death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>tislelizumab+anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will be administrate with dual drugs, tislelizumab plus anlotinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>For included participants, tislelizumab would be administrated 200mg q3w iv.</description>
    <arm_group_label>tislelizumab+anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.</description>
    <arm_group_label>tislelizumab+anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG scored 0 or 1, ≥18 years old, expected OS≥3 months;&#xD;
&#xD;
          -  Histology confirmed unresectable or metastatic gastric/gastroesophageal junction&#xD;
             adenocarcinoma or colorectal cancer;&#xD;
&#xD;
          -  ≥1 evaluable lesion based on RECIST 1.1;&#xD;
&#xD;
          -  Patients received PD-1/PD-L1 in the last treatment line, and should meet following&#xD;
             conditions:&#xD;
&#xD;
             i) there was no severe immune-related adverse events, ii) the duration between tumor&#xD;
             progression and screening should be 3-12 weeks, iii) the best evaluation results&#xD;
             should be PR or CR when receiving PD-1/PD-L1 treatment but progression was confirmed&#xD;
             in the latest evaluation, iv) patients were diagnosed with special pathology subtypes,&#xD;
             that are sensitive to immunotherapy, such as dMMR, MSI-H tumors, or gastric cancer&#xD;
             with PD-L1 CPS≥10, PFS≥6 months in the last treatment line;&#xD;
&#xD;
          -  laboratory test should meet following standard: i) HB≥90g/l, neutrophils≥1.5*10^9/L,&#xD;
             plt≥100*10^9, ii) ALT and AST&lt;2.5xULN (5ULN for liver metastatic patients),&#xD;
             TBIL≤2×ULN, Cr≤1.5×ULN, and Ccr&gt;50μmol/L iii) APTT, INR and PT≤1.5×ULN iv) LVEF≥50%&#xD;
&#xD;
          -  for female participants, Hcg should be negative and both male and female participants&#xD;
             should have contraception measures&#xD;
&#xD;
          -  participants should be informed consent, and voluntary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  received anlotinib or other TKIs previously;&#xD;
&#xD;
          -  allergic to other monoclonal antibody before the treatment;&#xD;
&#xD;
          -  diagnosed with other malignancy in last five years (cured skin basal carcinoma,&#xD;
             prostate cancer or cervical caner in situ were excluded)&#xD;
&#xD;
          -  concurrent with other active autoimmune disease;&#xD;
&#xD;
          -  any condition that require immune suppressor, such as cortisol (&gt;10mg/d prednisone&#xD;
             equally), CTX;&#xD;
&#xD;
          -  conditions affect oral absorption (eg: dysphagia, intestinal obstruction; chronic&#xD;
             diarrhea);&#xD;
&#xD;
          -  uncontrolled pleural effusion, hydropericardium and seroperitoneum;&#xD;
&#xD;
          -  brain metastasis;&#xD;
&#xD;
          -  received other anti-tumor treatment in past 3 weeks, eg: surgery, radiotherapy, target&#xD;
             therapy, immunotherapy, and traditional Chinese therapy (target therapy less than 5&#xD;
             half-life period, 5-Fu less than 14 days were excluded);&#xD;
&#xD;
          -  concurrent with uncontrolled other diseases, i) hypertension (&gt;150/90mmHg) ii)&#xD;
             unstable angina pectoris, ≥ level 2 heart failure, arrhythmia within last 6 months;&#xD;
             iii) clinical meaningful liver disease, eg: active HBV/HCV hepatitis; iv) HIV&#xD;
             positive; v) uncontrolled diabetes; vi) urine protein ≥++ or 24h urine protein &gt;1g;&#xD;
&#xD;
          -  injected vaccine in past 4 weeks, or administrated with antibiotics;&#xD;
&#xD;
          -  investigator assumed improper conditions, such as mental disease, family or society&#xD;
             factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

